Agenus Inc.
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.49
Price-9.32%
-$0.77
1Y
Price
Market Cap
$311.902m
Small
Price/Earnings 3y Avg5y Avg
3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+161.5%
EBITDA Margin+116.3%
Net Profit Margin-106.6%
Free Cash Flow Margin+161.5%
EBITDA Margin+116.3%
Net Profit Margin-106.6%
Free Cash Flow MarginRevenue
$123.866m
+8.5%
1y CAGR-5.0%
3y CAGR+11.1%
5y CAGREarnings
$64.607m
+56080.0%
1y CAGR+18729.2%
3y CAGR+14044.0%
5y CAGREPS
$1.66
-
1y CAGR+41.0%
3y CAGR+33.8%
5y CAGRBook Value
-$227.983m
$186.456m
Assets$414.439m
Liabilities$304.464m
DebtDebt to Assets
163.3%
2.4x
Debt to EBITDAFree Cash Flow
-$87.528m
+44.9%
1y CAGR+25.7%
3y CAGR+18.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company